BDRX Relative Valuation
BDRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BDRX is overvalued; if below, it's undervalued.
Historical Valuation
Biodexa Pharmaceuticals PLC (BDRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -53.04. The fair price of Biodexa Pharmaceuticals PLC (BDRX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.42
Fair
-7.31
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Biodexa Pharmaceuticals PLC. (BDRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.27. The thresholds are as follows: Strongly Undervalued below -6.76, Undervalued between -6.76 and -4.01, Fairly Valued between 1.48 and -4.01, Overvalued between 1.48 and 4.22, and Strongly Overvalued above 4.22. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.21
EV/EBIT
Biodexa Pharmaceuticals PLC. (BDRX) has a current EV/EBIT of 0.21. The 5-year average EV/EBIT is -0.12. The thresholds are as follows: Strongly Undervalued below -0.98, Undervalued between -0.98 and -0.55, Fairly Valued between 0.31 and -0.55, Overvalued between 0.31 and 0.73, and Strongly Overvalued above 0.73. The current Forward EV/EBIT of 0.21 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Biodexa Pharmaceuticals PLC. (BDRX) has a current PS of 0.00. The 5-year average PS is 45.32. The thresholds are as follows: Strongly Undervalued below -132.65, Undervalued between -132.65 and -43.66, Fairly Valued between 134.30 and -43.66, Overvalued between 134.30 and 223.29, and Strongly Overvalued above 223.29. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Biodexa Pharmaceuticals PLC. (BDRX) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.10. The thresholds are as follows: Strongly Undervalued below -0.40, Undervalued between -0.40 and -0.25, Fairly Valued between 0.05 and -0.25, Overvalued between 0.05 and 0.20, and Strongly Overvalued above 0.20. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Biodexa Pharmaceuticals PLC. (BDRX) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.04. The thresholds are as follows: Strongly Undervalued below -0.28, Undervalued between -0.28 and -0.16, Fairly Valued between 0.07 and -0.16, Overvalued between 0.07 and 0.19, and Strongly Overvalued above 0.19. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Biodexa Pharmaceuticals PLC (BDRX) has a current Price-to-Book (P/B) ratio of 0.10. Compared to its 3-year average P/B ratio of 0.57 , the current P/B ratio is approximately -82.67% higher. Relative to its 5-year average P/B ratio of 0.34, the current P/B ratio is about -70.95% higher. Biodexa Pharmaceuticals PLC (BDRX) has a Forward Free Cash Flow (FCF) yield of approximately -864.05%. Compared to its 3-year average FCF yield of -337.52%, the current FCF yield is approximately 156.00% lower. Relative to its 5-year average FCF yield of -226.58% , the current FCF yield is about 281.34% lower.
0.10
P/B
Median3y
0.57
Median5y
0.34
-864.05
FCF Yield
Median3y
-337.52
Median5y
-226.58
Competitors Valuation Multiple
The average P/S ratio for BDRX's competitors is 0.00, providing a benchmark for relative valuation. Biodexa Pharmaceuticals PLC Corp (BDRX) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BDRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BDRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Biodexa Pharmaceuticals PLC (BDRX) currently overvalued or undervalued?
Biodexa Pharmaceuticals PLC (BDRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -53.04. The fair price of Biodexa Pharmaceuticals PLC (BDRX) is between to according to relative valuation methord.
What is Biodexa Pharmaceuticals PLC (BDRX) fair value?
BDRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Biodexa Pharmaceuticals PLC (BDRX) is between to according to relative valuation methord.
How does BDRX's valuation metrics compare to the industry average?
The average P/S ratio for BDRX's competitors is 0.00, providing a benchmark for relative valuation. Biodexa Pharmaceuticals PLC Corp (BDRX) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Biodexa Pharmaceuticals PLC (BDRX) as of Jan 08 2026?
As of Jan 08 2026, Biodexa Pharmaceuticals PLC (BDRX) has a P/B ratio of 0.10. This indicates that the market values BDRX at 0.10 times its book value.
What is the current FCF Yield for Biodexa Pharmaceuticals PLC (BDRX) as of Jan 08 2026?
As of Jan 08 2026, Biodexa Pharmaceuticals PLC (BDRX) has a FCF Yield of -864.05%. This means that for every dollar of Biodexa Pharmaceuticals PLC’s market capitalization, the company generates -864.05 cents in free cash flow.
What is the current Forward P/E ratio for Biodexa Pharmaceuticals PLC (BDRX) as of Jan 08 2026?
As of Jan 08 2026, Biodexa Pharmaceuticals PLC (BDRX) has a Forward P/E ratio of -7.31. This means the market is willing to pay $-7.31 for every dollar of Biodexa Pharmaceuticals PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Biodexa Pharmaceuticals PLC (BDRX) as of Jan 08 2026?
As of Jan 08 2026, Biodexa Pharmaceuticals PLC (BDRX) has a Forward P/S ratio of 0.00. This means the market is valuing BDRX at $0.00 for every dollar of expected revenue over the next 12 months.